SonoVoice, Inc. is proud to announce a significant milestone in our journey to revolutionize clinical vocal health assessment. We have successfully raised $50,000 in funding, a crucial investment that will accelerate the development of our handheld medical device, which uniquely combines acoustic and aerodynamic measures with AI-assisted analysis. Designed to support precise clinical evaluations, our technology targets an underserved need: the 30 million Americans who experience voice disorders annually. This investment is more than just financial backingโit is a vote of confidence in our mission to enhance the accessibility and accuracy of evidence-based voice evaluation and training.
At SonoVoice, we are driven by a passion for innovation and improved patient outcomes. Our device, co-invented by leading researchers from Duke University, New York University, and NC State University, stands at the intersection of advanced healthcare technology and user-friendly design. By integrating state-of-the-art acoustic data with aerodynamic metrics analyzed through intelligent algorithms, our solution promises a more comprehensive view of vocal health. The funding will empower us to further refine this technology, expand clinical trials, and move closer to making our device available in mainstream clinical settings.
This achievement marks a pivotal moment for our team, underscoring our commitment to changing how clinicians monitor and treat voice disorders. As we embark on the next phase of our journey, we remain dedicated to rigorous scientific validation and continuous product improvement. We are excited to leverage this new capital to push the boundaries of vocal health technology, ensuring that every patient has access to accurate, efficient, and life-enhancing care.
